Australia's most trusted
source of pharma news
Tuesday, 30 April 2024
Posted 12 April 2024 AM
Vertex has boosted its nephrology pipeline with the AU$7.5 billion purchase of Alpine Immune Sciences, touting its lead drug as a 'pipeline in a product' and comparing its potential to the wildly successful AbbVie biologic, Humira, which had an extraordinary run as the world's top selling drug.
The pharma announced the purchase this week, with the main attraction being povetacicept, a Phase 2 drug which has shown potential best-in-class efficacy in IgA nephropathy (IgAN).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.